Last reviewed · How we verify
Sitagliptin and Gliclazide — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Sitagliptin and Gliclazide (Sitagliptin and Gliclazide) — Zhibin Xu.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sitagliptin and Gliclazide TARGET | Sitagliptin and Gliclazide | Zhibin Xu | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sitagliptin and Gliclazide CI watch — RSS
- Sitagliptin and Gliclazide CI watch — Atom
- Sitagliptin and Gliclazide CI watch — JSON
- Sitagliptin and Gliclazide alone — RSS
Cite this brief
Drug Landscape (2026). Sitagliptin and Gliclazide — Competitive Intelligence Brief. https://druglandscape.com/ci/sitagliptin-and-gliclazide. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab